At disease relapse, almost a quarter of patients received only locoregional treatment and all EGFR-mutant patients received an EGFR-TKI (20, 21), as described in previous similar series of EGFR mutant NSCLC, eventually followed by a variety of combination therapies (22, 23). Here, EGFR is linked to non-small cell lung carcinoma.